Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

ll growth.

EpiCept's proprietary apoptosis screening technology can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells through the use of chemical genetics and its proprietary live cell high-throughput caspase-3 screening technology. Chemical genetics is a research approach investigating the effect of small molecule drug candidates on the cellular activity of a protein, enabling researchers to determine the protein's function. Using this approach with its proprietary caspase-3 screening technology, EpiCept researchers can focus their investigation on the cellular activity of small molecule drug candidates and their relationship to apoptosis.

This combination of chemical genetics and caspase-3 screening technology allows EpiCept's researchers to discover and rapidly test the effect of small molecules on pathways and molecular targets crucial to apoptosis, and gain insights into their potential as new anticancer agents. This screening technology is particularly versatile and can be adapted for almost any cell type that can be cultured, as well as measure caspase activation inside multiple cell types (e.g., cancer cells, immune cells, or cell lines from different organ systems or genetically engineered cells). This allows researchers to find potential drug candidates that are selective for specific cancer types, which may help identify candidates that provide increased therapeutic benefit and reduced toxicity.

EpiCept has identified several families of compounds with potentially novel mechanisms that induce apoptosis in cancer cells. Several compounds from within these families have progressed to lead drug candidate status with proven pre-clinical efficacies in tumor models and identified molecular targets.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates wi
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... DALLAS , September 17, 2014 ... Electronics Market by Component (Sensor, Battery, Memory Device, Display, ... and Fitness & Wellness), and by Geography - Global ... of medical electronics market is expected to reach $56.50 ... from 2014 to 2020. Browse 235 market ...
(Date:9/17/2014)... 2014  NuView Life Sciences, Inc. (NuView) announced ... agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) to ... biomarker to detect cancers of the breast and ... diagnostic-imaging applications. NuView retains all rights for the ... urine screen applications. Under the terms ...
(Date:9/17/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ... $4 million milestone payment from Achaogen, Inc. (NASDAQ: ... of a Phase 3 study of plazomicin in ... infections.  The Phase 3 study is designed as ... safety of plazomicin compared to colistin in patients ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
... Belt Technologies, Inc., a Pittsburgh based medical device company ... use in orthopaedic and neurosurgery procedures, has closed on ... financing. The round was led by private investors ... Works (Pittsburgh) and consisted of both new investments and ...
... Sept. 30 Law firm Clifford Chance, as international counsel, ... with Wyeth under China,s Anti-Monopoly Law. The clearance was issued ... , Competition approval from the Chinese authorities was one of ... The EU has already approved the deal; decisions are awaited ...
Cached Medicine Technology:Blue Belt Technologies, Inc. Closes Series A Financing 2Blue Belt Technologies, Inc. Closes Series A Financing 3Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth 2
(Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
(Date:9/17/2014)... 2014 (HealthDay News) -- Positive messages about the health ... the habit, a new study suggests. Although smokers ... "loss-framed" messages about the harmful effects of smoking, researchers ... want benefit more from "gain-framed," or positive, messages about ... concluded that using a mix of both types of ...
(Date:9/17/2014)... Many countries choose to kill all infected poultry ... number of poultry exceeds 10 billion in China. Epidemic ... huge losses. Therefore, it is quite necessary to immunize ... vaccines have been used for more than 10 years ... use H5N1 avian influenza vaccines voluntarily 10 years ago ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 StartX ... revealed 12 companies raising rounds of funding at its ... few hundred investors and media, was the first such ... located next to the university. The presentations were delivered ... adjacent to StartX-QB3 Labs, a 2,000 square foot life ...
(Date:9/17/2014)... The Delta Dental Community Care Foundation announced today ... Health Foundation: America’s ToothFairy (NCOHF) to support oral health ... Zone Program® in California. , The Orange County NCOHF ... local constituent groups and stakeholders in a comprehensive approach ... its devastating effects on local families. The support of ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2
... multi-center U.S. registry on the efficacy of carotid stenting ... are at high risk for standard surgical therapy.// ... CAPTURE (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare ... Cardiology’s 55th Annual Session in Atlanta. The multi-center study ...
... with a friend will be more beneficial to health than ... Elizabeth Gould at Harvard University compared the costs and benefits ... and found that contrary to accepted wisdom, jogging was not ... Daily Mail. ,The researchers carried out series of ...
... Hopkins University School of Medicine said that genetic material in ... // , The researchers feel that it very ... of mutated human genes. ,Jef Boeke described about ... the yeast cells which is necessary for the stability of ...
... spells doom for global economic growth. According to bank economist ... a dent of two to six percentage out of global ... rate reductions and older populations, which will lead to continued ... Burns, has been getting Bay Street and investors to gear ...
... at the end of the tunnel. Those infected with human ... workplaces. // Employers will have to face legal charges if ... ,HIV causes acquired immune deficiency syndrome. The ministry of ... of HIV/AIDS, which will seek to protect the rights of ...
... and 170 suspected cases of meningococcimia or meningitis in New ... who are taking strict measures to check the spread of ... sure that family members and neighbors of infected persons are ... also distributing leaflets to educate people about the symptoms of ...
Cached Medicine News:Health News:Carotid Stenting Can Help Patients With Silent Disease 2Health News:Carotid Stenting Can Help Patients With Silent Disease 3Health News:Carotid Stenting Can Help Patients With Silent Disease 4
... anesthesia workstation provides an intelligent approach ... to provide true clinical benefits to ... the art computer technology integrates hemodynamic ... color touchscreen display panel. The open ...
... Cost effective technology in anesthesia., ,Whether ... manual ventilation, the operating theater or as ... integrated monitoring, the Aliseo product family allows ... ,With three product models, you have ...
... in facilities where space is a premium ... gas delivery technologies with an ergonomic and ... functionality of the Draeger Infinity patient monitoring ... workplace environment that is a sound investment ...
... A new level of excellence and ... advanced anesthesia delivery system with basic ventilation ... industry leading excellence of the Aestiva/5 Anesthesia ... compact design - it features a configurable ...
Medicine Products: